Sunday, September 13, 2026
RSS

Pharmaceutical

Canadian Healthcare Budgets Under Pressure: Implications for Pharmaceutical Investors

New cancer drugs are straining Canadian healthcare budgets, raising concerns for investors in the pharmaceutical sector.

By Marcus Rivera • September 13, 2026
Energy

Oil Prices Surge: What It Means for North American Energy Investors

U.S. crude oil prices exceed $102 per barrel, raising questions for energy investors amid geopolitical tensions.

Sarah Chen • Sep 13
Tech

Oracle's Restructuring Costs: Implications for Investors and Market Dynamics

Oracle's restructuring costs have surged to $2.8 billion, raising concerns about its market competitiveness and earnings outlook.

James McAllister • Sep 13
Trade with the conviction of the 1%.

Institutional-grade market intelligence delivered before the opening bell.

By subscribing, I agree to receive marketing emails and alerts. View our Privacy Policy. You may unsubscribe at any time.

More Stories
Pharmaceutical

Activist Investor Backs Seraxis Takeover of Sernova: Implications for the Canadian Biotech Sector

A shareholder's support for Seraxis's takeover of Sernova signals potential shifts in the Canadian biotech landscape.

Marcus Rivera • Sep 12, 2026
Pharmaceutical

FDA Delays Exelixis' Zanzalintinib Review: What It Means for Investors

The FDA's delay in reviewing Exelixis' zanzalintinib raises questions for investors about future revenue and growth.

Sarah Chen • Sep 12, 2026
Energy

Crude Oil Prices Surge Past $102: Implications for US and Canadian Energy Markets

Crude oil prices have surpassed $102, driven by geopolitical tensions and supply concerns, impacting US and Canadian ene…

James McAllister • Sep 12, 2026
Markets & Money

Consumer Sentiment Plummets as Inflation Fears Rise, Potential Fed Rate Hike Looms

Consumer sentiment drops to 47.8, sparking inflation concerns and signaling possible Fed interest rate hikes.

Marcus Rivera • Sep 11, 2026
Pharmaceutical

Exelixis Faces Setback as FDA Extends Review of Zanzalintinib

Exelixis faces uncertainty as the FDA prolongs its review of zanzalintinib, raising questions about future revenue and s…

Sarah Chen • Sep 11, 2026
Markets & Money

SPS Commerce Stock Jumps Amid Acquisition Talks with GTCR

SPS Commerce shares surged as GTCR expresses acquisition interest. Explore the implications for the tech sector.

James McAllister • Sep 11, 2026
Energy

NextEra and Dominion Merger: A New Era for U.S. Utilities

The merger between NextEra Energy and Dominion Energy could reshape the U.S. utility landscape, impacting customers and …

Marcus Rivera • Sep 11, 2026
Pharmaceutical

Merck and Moderna's mRNA Breakthrough: Implications for the Future of Cancer Treatment

The Phase 3 INTerpath-001 trial results present significant implications for Merck and Moderna's cancer treatment strate…

Sarah Chen • Sep 11, 2026
Pharmaceutical

Quantum BioPharma's FDA Clearance: A Game Changer for MS Treatment

Quantum BioPharma's FDA clearance for Lucid-MS could reshape MS treatment and enhance investor confidence.

James McAllister • Sep 11, 2026